General Information
Niraparib, sold under the brand name Zejula, is a cytotoxic targeted therapy. This medication is classified as a PARP (poly ADP ribose polymerase) inhibitor.
About the API
Technology
Synthetic
Therapeutic category
Oncology
Available formulations
Oral Solid